Biodecision
Executive Summary
Contract laboratory announces Dec. 13 completion of private equity financing to help resume full operations. The new funding follows a three-week inspection by FDA in September and an agency decision to resume "accepting for review drug product applications supported by new clinical studies and analytical work conducted by Biodecision".